Puma Biotechnology reported $9.48M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Daiichi Sankyo JPY 733.05B 40.68B Jun/2026
Exelixis USD 29.87M 1.14M Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Moderna USD 313M 33M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Takeda JPY 1.44T 6.17B Sep/2026
TG Therapeutics USD 194.32M 46.35M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026